Lilly's profit doubled in the fourth quarter, driven by its diabetes and obesity treatments Mounjaro and Zepbound, while ...

It does not provide Zepbound for people whose doctors have prescribed it off-label. Off-label means that a doctor prescribes a medication for a reason or at a dose the FDA has not approved.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing type 2 diabetes. Adults without diabetes lost 15% to 20.9% of their body weight, depending on the dosage.